Back to News
Market Impact: 0.2
Roth Capital Initiates Coverage of Guardant Health at Buy
Source: Nasdaq
Analyst InsightsHealthcare & Biotech
On October 23, 2026, Roth Capital initiated coverage of Guardant Health with a Buy recommendation. The report provides no price target or other financial details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
GH0.45
More News
- Biotech stocks are surging. How investors can play the new drug innovation boom
- Goldman says these top tech stocks have plenty of upside ahead of earnings
- ProPetro’s 49% decline: how Fair Value spotted the warning signs
- Persistent Oil Prices Threaten Inflation Outlook
- IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
- Could France’s debt crisis spread across Europe?